How should diabetic nephropathy be managed regarding glycemic control (target HbA1c ~7 %), blood pressure control (≤130/80 mm Hg), use of sodium‑glucose co‑transporter‑2 inhibitors or glucagon‑like peptide‑1 receptor agonists, angiotensin‑converting enzyme inhibitor or angiotensin receptor blocker therapy, possible addition of finerenone, lifestyle modifications (low‑sodium diet, moderate protein intake, weight loss, exercise, smoking cessation), statin therapy, avoidance of nephrotoxic agents, regular monitoring of renal function and albuminuria, and criteria for nephrology referral?

Management of Diabetic Nephropathy

Diabetic nephropathy requires a comprehensive, algorithm-driven approach centered on SGLT2 inhibitors and RAAS blockade as foundational therapies, with strict glycemic and blood pressure targets tailored to individual patient characteristics. 1

Glycemic Control

Target HbA1c

• Aim for HbA1c ~7.0% (53 mmol/mol) in most patients to prevent or delay progression of diabetic kidney disease. 1
• Individualize targets based on patient factors:
  • HbA1c <6.5% may be appropriate for younger patients without hypoglycemia risk or comorbidities. 1
  • HbA1c 7.0-8.0% is acceptable for patients with high hypoglycemia risk, multiple comorbidities, or limited life expectancy. 1
  • Avoid targets <7.0% in patients at risk of hypoglycemia. 1
• Monitor HbA1c every 3 months until target achieved, then every 3-6 months. 1

Antihyperglycemic Medication Algorithm

First-Line Therapy (eGFR ≥30 mL/min/1.73 m²):

• Metformin should be initiated as foundational therapy. 1
• SGLT2 inhibitor (dapagliflozin 10 mg, empagliflozin 10 mg, or canagliflozin 100 mg daily) must be started immediately for cardiorenal protection, independent of glycemic control needs. 1, 2
  • SGLT2 inhibitors reduce CKD progression by ~30% (HR 0.70), cardiovascular death by 22-38%, and heart failure hospitalization by 31-39%. 2
  • Continue SGLT2 inhibitors even as eGFR declines below 30 mL/min/1.73 m², as cardiorenal benefits persist down to eGFR 20 mL/min/1.73 m². 2, 3, 4
  • Expect and tolerate a transient eGFR decline of up to 25% after initiation—this reflects hemodynamic changes, not kidney injury, and is not an indication to discontinue. 1, 4

Second-Line Therapy:

• Long-acting GLP-1 receptor agonist (dulaglutide, semaglutide, or liraglutide) should be added if glycemic targets are not met with metformin and SGLT2 inhibitor, or if these agents cannot be used. 1, 3
• GLP-1 RAs reduce cardiovascular events and may prevent progression to macroalbuminuria or further eGFR decline. 1, 3
• Combination SGLT2 inhibitor + GLP-1 RA provides additive cardiorenal protection. 2, 5
• No dose adjustment required for GLP-1 RAs in CKD stage 3-4 (eGFR >15 mL/min/1.73 m²). 3

Metformin Dose Adjustment in CKD:

• Reduce metformin dose when eGFR <45 mL/min/1.73 m² (maximum 500-1000 mg daily). 1, 3
• Discontinue metformin when eGFR <30 mL/min/1.73 m² due to lactic acidosis risk. 1, 3

Medications to Avoid:

• Sulfonylureas carry unacceptable hypoglycemia risk in CKD and should be discontinued, especially in stage 3 or higher. 2
• Avoid nephrotoxic agents including NSAIDs and radiocontrast media (ensure careful hydration if contrast unavoidable). 1

---

Blood Pressure Control

Target Blood Pressure

• Target systolic BP <130 mm Hg (individualized, not <120 mm Hg) and diastolic BP <80 mm Hg. 1, 2
• For patients aged >65 years, target systolic BP 130-139 mm Hg and diastolic <80 mm Hg (not <70 mm Hg). 1
• BP <120/80 mm Hg may be appropriate for select patients at high stroke risk. 1

RAAS Blockade (Cornerstone Therapy)

• ACE inhibitor or ARB therapy is mandatory for all patients with diabetic nephropathy and any degree of albuminuria. 1
  • ACE inhibitors delay progression of nephropathy in hypertensive type 1 diabetic patients with any albuminuria. 1
  • ACE inhibitors and ARBs delay progression to macroalbuminuria in hypertensive type 2 diabetic patients with microalbuminuria. 1
• Titrate to maximum tolerated dose (e.g., losartan 100 mg daily, lisinopril 40 mg daily, ramipril 10 mg daily). 2
• If one class is not tolerated, substitute the other. 1
• Monitor serum potassium closely after initiation or dose escalation, especially when combined with SGLT2 inhibitors (which may mitigate hyperkalemia). 1, 2

Additional Antihypertensive Agents

• If BP target not achieved with RAAS blockade alone, add:
  • Thiazide or thiazide-like diuretic (e.g., hydrochlorothiazide 12.5-25 mg daily, chlorthalidone 12.5-25 mg daily). 2
  • Cardioselective β-blocker if compelling indication (heart failure, coronary disease) exists. 2
  • Dihydropyridine calcium channel blocker (e.g., amlodipine 5-10 mg daily) as additional therapy. 1
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are not more effective than placebo for slowing nephropathy progression and should be restricted to additional BP control only. 1

---

Finerenone (Nonsteroidal Mineralocorticoid Receptor Antagonist)

• Consider adding finerenone in patients with type 2 diabetes, CKD (eGFR ≥25 mL/min/1.73 m²), and albuminuria despite maximal RAAS blockade. 1, 6
• Finerenone reduces albuminuria in a dose-dependent manner when added to ACE inhibitor or ARB therapy. 6
• Dosing: Start finerenone 10-20 mg daily based on eGFR and potassium level. 6
• Monitor serum potassium closely—hyperkalemia leading to discontinuation occurred in 1.7-3.2% of patients in trials. 6

---

Lifestyle Modifications

Dietary Interventions

• Sodium restriction: <2 g/day (<5 g sodium chloride/day). 7
• Protein intake:
  • 0.8 g/kg/day (adult RDA, ~10% of daily calories) once overt nephropathy develops. 1, 7
  • Avoid high protein intake (≥1.3 g/kg/day) in adults with CKD at risk of progression. 1
  • Further restriction to 0.6 g/kg/day may slow eGFR decline in selected patients with declining GFR, but requires expert dietitian supervision to prevent malnutrition. 1
  • Do not restrict protein below 0.8 g/kg/day in non-dialysis CKD without specialized monitoring. 7

Physical Activity

• Recommend moderate-intensity physical activity for cumulative duration of ≥150 minutes per week. 1, 7
• Counsel patients to avoid sedentary behavior. 1

Smoking Cessation

• Smoking cessation is mandatory—smoking accelerates nephropathy progression. 1

Weight Management

• Weight loss improves glycemic control and reduces albuminuria in overweight/obese patients. 1

---

Lipid Management

• Initiate statin therapy for all patients with diabetic nephropathy to reduce cardiovascular risk. 1
• Target LDL-C <70 mg/dL given elevated cardiovascular risk with diabetes and CKD. 7
• Lipid management should be part of a multifactorial intervention strategy addressing BP, glycemic control, and antiplatelet therapy where indicated. 1

---

Monitoring Renal Function and Albuminuria

Frequency of Monitoring

• Annual screening for microalbuminuria in:
  • Type 1 diabetic patients who have had diabetes ≥5 years. 1
  • All type 2 diabetic patients starting at diagnosis. 1
• More frequent monitoring (every 3-6 months):
  • UACR ≥300 mg/g. 1
  • eGFR 30-60 mL/min/1.73 m² (CKD stage 3). 1
  • CKD stage 3b-4 (eGFR <45 mL/min/1.73 m²). 1
• Repeat testing when:
  • Change in clinical status indicating rapid progression. 1
  • New medications started (SGLT2 inhibitor, ACE inhibitor, ARB). 1

Interpretation of eGFR and UACR

• Combined eGFR and UACR improve risk stratification and diagnostic accuracy. 1
• Transient eGFR reduction of up to 25% after initiating SGLT2 inhibitor or RAAS blocker is expected and reflects hemodynamic changes, not intrinsic renal disease. 1, 4
• Do not discontinue SGLT2 inhibitor or RAAS blocker for acute eGFR decline <25% unless renal artery stenosis suspected. 1, 4

---

Criteria for Nephrology Referral

Refer to nephrologist when:

• eGFR <45 mL/min/1.73 m² for coordinated care to slow progression. 1
• eGFR <30 mL/min/1.73 m² (strongly recommended). 1
• Persistent UACR ≥300 mg/g despite treatment. 1
• DKD progresses to a new CKD category (e.g., stage 3a to 3b). 1
• Abrupt, sustained eGFR decline >5 mL/min/1.73 m² per year. 1
• Difficulty managing hypertension or hyperkalemia. 1

Benefits of nephrology referral:

• Increases appropriate use of RAAS blockers. 1
• Optimizes management of anemia, CKD mineral-bone disorder, and other complications. 1
• Prepares patients for kidney replacement therapy. 1

---

Common Pitfalls and Caveats

• Do not discontinue SGLT2 inhibitors for transient eGFR decline—this is hemodynamic and expected. 1, 4
• Do not combine ACE inhibitor + ARB—dual RAAS blockade increases hyperkalemia and AKI risk without additional benefit. 1
• Do not use sulfonylureas in CKD stage 3 or higher—hypoglycemia risk is unacceptable. 2
• Do not restrict protein <0.8 g/kg/day without dietitian supervision—risk of malnutrition and muscle wasting. 1
• Temporarily withhold SGLT2 inhibitor during prolonged fasting, major surgery, or acute critical illness to reduce ketosis risk. 3
• Monitor potassium closely when combining RAAS blocker + finerenone or RAAS blocker + SGLT2 inhibitor—hyperkalemia risk exists but is often mitigated by SGLT2 inhibitor's kaliuretic effect. 2, 6